Aarti Drugs has approved a comprehensive leadership transition effective October 1, 2026, elevating Rashesh C. Gogri to Chairman and appointing Adhish P. Patil as Managing Director. The Board of Directors also accepted the early retirement of Prakash M. Patil, who has served as Chairman and Managing Director since 2014, citing the need for an orderly succession plan. This restructuring aims to maintain strategic continuity while injecting fresh leadership into key executive roles ahead of Prakash M. Patil’s term expiry in May 2027.

Key Leadership Changes

The Board meeting held on July 31, 2026, finalized several critical appointments and re-appointments subject to shareholder approval at the ensuing Annual General Meeting (AGM). The changes reflect a blend of internal promotions and continuity in governance.

Rashesh C. Gogri, who has been Managing Director since September 2014, brings over 27 years of experience in production, marketing, and project implementation. He also serves as Vice-Chairman & Managing Director of Aarti Industries Limited. Adhish P. Patil, currently Chief Financial Officer since April 2014, holds an MBA in Finance and Marketing from the University of Florida’s Warrington College of Business Administration. His appointment is contingent upon shareholder approval.

Additional Board Appointments

The Board also approved the following appointments and re-appointments, all subject to shareholder approval:

• Nilesh B. Patil: Appointed as Whole-time Director for a five-year term starting from the conclusion of the AGM, replacing Uday M. Patil who retires by rotation and has not offered himself for re-appointment. Nilesh B. Patil has been with the company for over 33 years.
• Harshit M. Savla: Re-appointed as Joint Managing Director for five years effective June 1, 2027.
• Harit P. Shah: Re-appointed as Whole-time Director for five years effective June 1, 2027.
• Independent Directors: Hasmukh B. Dedhia, Ajit E. Venugopalan, and Sandeep M. Joshi are re-appointed for second terms of five years each, effective March 29, 2027.

Prakash M. Patil will continue to provide guidance and strategic support to ensure a smooth transition despite his early departure from executive roles. The Board expressed deep appreciation for his visionary leadership since the company’s inception in 1984.

Committee Reconstitution

Consequent to these changes, the Board reconstituted its committees effective October 1, 2026:

• Audit Committee: Chaired by Hasmukh B. Dedhia, with members including Ankit V. Paleja, Neha R. Gada, Ajit E. Venugopalan, Rashesh C. Gogri, and Adhish P. Patil.
• Nomination and Remuneration Committee: Chaired by Neha R. Gada, with members Bhaskar N. Thorat, Ankit V. Paleja, and Rashesh C. Gogri.
• Risk Management Committee: Chaired by Rashesh C. Gogri, with a broad membership including Adhish P. Patil, Harshit M. Savla, Harit P. Shah, Narendra J. Salvi, Nilesh B. Patil, Ankit V. Paleja, Bhaskar N. Thorat, and Dhanaji L. Kakade.
• Corporate Social Responsibility Committee: Chaired by Bhaskar N. Thorat, with Adhish P. Patil and Rashesh C. Gogri as members.
• Finance and Investment Committee: Chaired by Rashesh C. Gogri, with Adhish P. Patil, Harshit M. Savla, Harit P. Shah, and Nilesh B. Patil as members.

What the Numbers Show

The retention of senior leadership within the organization signals stability for investors. By promoting executives who have grown within the company, Aarti Drugs mitigates the risks often associated with external hires. The transition maintains the company’s long-term strategic direction, focusing on scaling operations in Active Pharmaceutical Ingredients (APIs) and specialty chemicals through its 14 manufacturing facilities across Maharashtra, Gujarat, and Himachal Pradesh. The early retirement of Prakash M. Patil, whose term was set to expire in May 2027, underscores a proactive approach to governance and succession planning.

Aarti Drugs has been directed by the Gujarat Pollution Control Board (GPCB) to shut down its Amines plant, marking a significant regulatory action against the pharmaceutical company. The order reflects the GPCB's mandate to enforce environmental compliance standards across industrial operations in the state.

Regulatory Action by GPCB

The Gujarat Pollution Control Board issued the shutdown directive specifically targeting Aarti Drugs' Amines plant. The GPCB is the statutory authority responsible for monitoring and regulating pollution-related activities of industries operating within Gujarat, and such orders are issued when units are found to be in contravention of prescribed environmental norms.

Impact on Operations

The shutdown order pertains to the Amines plant of Aarti Drugs, which forms a part of the company's manufacturing operations. Compliance with such regulatory directives is mandatory, and the company will be required to address the concerns raised by the GPCB before resuming operations at the affected facility.